Sarepta Accused Of Misleading Investors On MD Drug
A Sarepta Pharmaceuticals Inc. shareholder filed a class action against the company in Massachusetts federal court Monday, alleging it intentionally misled investors about muscular dystrophy drug eteplirsen's chances of hitting the...To view the full article, register now.
Already a subscriber? Click here to view full article